NBIO — Nascent Biotech Balance Sheet
0.000.00%
- $0.50m
- $0.51m
Annual balance sheet for Nascent Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.003 | 0.001 | 0.094 | 0.172 | 0.372 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | 0.75 | 0 | — | — |
| Prepaid Expenses | |||||
| Total Current Assets | 0.003 | 0.751 | 0.105 | 0.255 | 0.552 |
| Total Assets | 0.003 | 0.751 | 0.105 | 0.255 | 0.552 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.88 | 1.22 | 0.777 | 1.55 | 0.809 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 2.88 | 1.22 | 0.777 | 1.55 | 0.809 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -2.88 | -0.473 | -0.671 | -1.3 | -0.257 |
| Total Liabilities & Shareholders' Equity | 0.003 | 0.751 | 0.105 | 0.255 | 0.552 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |